July 11, 2017
BioMarin Pharmaceutical Inc. announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A.
Read MoreJuly 6, 2017
Swedish Orphan Biovitrum AB and Bioverativ Inc. today announces that new data from their extended half-life therapies, Alprolix® (eftrenonacog alfa)([Coagulation Factor IX (Recombinant), Fc Fusion Protein] and Elocta® (efmoroctocog alfa), marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]) in the United States, Japan and Canada, will be presented at the International Society on Thrombosis […]
Read MoreJuly 6, 2017
Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress.
Read MoreJuly 3, 2017
The first results from the Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE) will be presented at the International Society of Thrombosis and Haemostasis Congress 2017, to be held in Berlin, Germany, from July 8th to 13th.
Read MoreJuly 3, 2017
Bayer AG announced today that new data from its portfolios in thrombosis and hematology will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 26th Biennial Congress and 63rd Annual Scientific and Standardization Committee (SSC) Meeting, which will take place in Berlin, Germany, from July 8 to 13.
Read MoreJuly 3, 2017
Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) congress from 8-13 July, in Germany.
Read More